{"prompt": "['Sponsor: APGD', 'ISN/Protocol 7465-CL-0301', 'EudraCT number 2017-003344-21', '- CONFIDENTIAL -', 'In case of mild hepatic impairment (total bilirubin > 1.25 ULN), paclitaxel should be started', 'at a dose of 135 mg/m\u00b2 Dose modifications for subjects receiving paclitaxel are detailed', 'below. Dose interruptions may last up to 6 weeks (2 cycles). Dose interruptions for subjects', \"who are responding to treatment may be extended beyond 6 weeks if the subject's toxicity\", 'does not otherwise require permanent discontinuation. Recommended dose modification', 'guidelines for subjects receiving paclitaxel are detailed below in Table 9', 'Please refer to local', 'product label or SmPC and institutional guidelines for further dose modifications.', 'Table 9', 'Recommended Dose Modification Guidelines Paclitaxel', 'Hold', 'Dose', 'Treatment', 'Toxicity', 'Grade', 'Occurrence', 'Treatment', 'Modification', 'Discontinuation', 'Peripheral', 'Grade 1, 2', 'No', '135 mg/m\u00b2', 'N/A', 'Neuropathy', 'Grade 3, 4', 'Yes', 'N/A', 'Discontinue upon', 'onset', 'Neutropenic', '1', 'Hold until', '135 mg/m\u00b2', 'fever (defined as', 'ANC', 'T> 100.5\u00b0F', '> 1,500/L', '(38.1\u00b0C) and', '2', 'Hold until', '100 mg/m\u00b2', 'ANC < 1,000/L)', 'ANC', '> 1,500/L', '3', 'yes', 'N/A', 'Yes', 'ANC: absolute neutrophil count; N/A: not applicable; T: temperature', '5.1.3 Previous and Concomitant Treatment (Medication and Nonmedication Therapy)', 'If the investigator determines that any of the following medications are deemed necessary to', 'provide adequate medical support to the subject, the subject must be withdrawn from further', 'administration of the study treatment:', 'Other investigational drugs', 'Chemotherapy or other medications intended for antitumor activity. This does not apply', 'to subjects with a history of breast cancer on adjuvant endocrine therapy, or for subjects', 'on agents intended for the treatment of bone metastasis (e.g., bisphosphonates, or RANK', 'ligand inhibitors).', 'Radiation therapy', 'Note: Radiation therapy to a symptomatic solitary lesion or to the bone may be', 'considered on an exceptional case-by-case basis after consultation with Sponsor. The', 'radiated lesion must be a non-target lesion per RECIST V1.1 and the subject must', 'have clear measurable disease outside the radiated field.', 'Arm A (enfortumab vedotin)', 'Subjects who are receiving strong cytochrome P450 (CYP): 3A4 inhibitors or P-pg', 'inhibitors concomitantly with EV should be closely monitored for adverse reactions.', '14 Sep 2020', 'Astellas', 'Page 65 of 143', 'Version 4.0 Incorporating Substantial Amendment 3']['Sponsor: APGD', 'ISN/Protocol 7465-CL-0301', 'EudraCT number 2017-003344-21', '- CONFIDENTIAL -', 'Arm B (Docetaxel)', 'Concomitant use of drugs that strongly inhibit or induce CYP3A4 may affect exposure to', 'docetaxel and should be avoided.', 'Arm B (Vinflunine)', 'Strong inhibitors of the CYP3A4 enzymes for subjects receiving vinflunine should be', 'avoided.', 'QT/QTc interval prolonging medicinal products should be avoided.', 'Arm B (Paclitaxel)', 'Caution should be exercised when paclitaxel is administered with strong inhibitors or', 'inducers of CYP3A4 and CYP2C8.', 'Please refer to the local package inserts for concomitant medication restrictions or', 'requirements for docetaxel, paclitaxel and vinflunine. All concomitant treatments will be', 'recorded in the eCRF or electronic data source unless otherwise specified.', '5.1.4 Treatment Compliance', 'The dose and schedule of EV, paclitaxel, docetaxel and vinflunine administered to each', 'subject will be recorded on the appropriate electronic case report form (eCRF) at every cycle.', 'Reasons for dose delay, reduction or omission will also be recorded.', 'If toxicities or adverse events occur on Day 1 of any cycle and EV cannot be administered,', 'then the start of the cycle may be delayed. If toxicities occur on Days 8 or 15 of any cycle', 'and require the dose to be held > 3 days, then the dose(s) must be eliminated, rather than', 'delayed. If a subject only receives day 1 and needs to skip days 8 and 15, the subject could', 'resume the next cycle as early as day 22 (new day 1), if the toxicity has resolved by then.', '5.2', 'Demographics and Baseline Characteristics', '5.2.1', 'Demographics', 'Demographic information will be collected for all subjects as allowed per local regulation', 'and will include date of birth, sex, race, ethnicity and tobacco use history (pack years).', '5.2.2', 'Medical History', 'Medical history will include all significant medical conditions other than urothelial cancer', 'that have resolved prior to informed consent or are ongoing at the time of consent. Details', 'that will be collected include the onset date and recovery date and Common Terminology', 'Criteria for Adverse Events (CTCAE) grade, if applicable for ongoing conditions.', '5.2.3 Diagnosis of the Target Disease, Severity, and Duration of Disease', 'For urothelial carcinoma, the following information including but not limited to will be', 'collected during the screening period, and be entered in the eCRF:', 'Date of initial diagnosis of the primary carcinoma, histological type, date of', 'histopathological or cytopathological diagnosis', '14 Sep 2020', 'Astellas', 'Page 66 of 143', 'Version 4.0 Incorporating Substantial Amendment 3']\n\n###\n\n", "completion": "END"}